China Health (301408.SZ): Sequoia Capital has completed a shareholding reduction of 1%.

Gelonghui, December 4th丨Chinese Health (301408.SZ) announced that the company recently received a notice from shareholder Sequoia Capital regarding the completion of its shareholding reduction plan and that the changes have reached 1%. It was learned that Sequoia Capital has cumulatively reduced its shares in the company by 4,000,000 shares through centralized bidding trade, accounting for 1% of the company's total share capital, and this shareholding reduction plan has been completed.

Gelonghui FinanceDec 4, 2024 18:40

Express News | Pharmaceutical commerce sector surged abnormally, lbx pharmacy chain joint stock hit the limit up.

BreakingsNov 28, 2024 14:18

A-shares fluctuation | Huaren Health falls by 4% as shareholders plan to reduce their shareholding by no more than 3%.

Gelonghui November 25th | Hua Ren Health (301408.SZ) is currently down by 4%, at 12 yuan, with a total market value falling below 5 billion yuan. In terms of news, shareholder ali health technology (China) Co., Ltd. intends to reduce its shareholding of the company by no more than 12.0003 million shares, with a reduction ratio not exceeding 3% of the total share capital of the company. It is reported that the company has announced a shareholding reduction plan three times in the past three years. (Gelonghui)

Gelonghui FinanceNov 25, 2024 14:41

Express News | Summary of shareholding reductions by listed companies on November 22nd (Table)

BreakingsNov 22, 2024 22:15

On November 25, A-shares investment risk avoidance: ali health shareholder plans to reduce shareholding by no more than 12 million shares.

Chinese health shareholder ali health plans to reduce its shareholding by no more than 12 million shares; Aoruida shareholder Qingcheng Kunshun plans to collectively reduce their shareholding by no more than 3%; Chuangshi technology holding shareholder and actual controller received a notification letter from the procuratorial organ; Jinlong machinery & electronic stated that the reported embezzlement incident involving relevant positions has received a notice of case filing; Ningbo techmation stated that the Italian company EEI does not directly produce and develop complete nuclear fusion devices; Tasly pharmaceutical group has temporarily suspended the clinical trial of AnMaiMu monoclonal antibody.

Gelonghui FinanceNov 22, 2024 22:05

Chinese Health: Report for the third quarter of 2024

SZSIOct 29, 2024 00:00 · Announcements